In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on OpGen Inc (OPGN), with a price target of $6. The company’s shares closed yesterday at $1.44.
Selvaraju noted:
“Our price target is derived from a market value of the firm at $79M. This includes a discounted cash flow analysis based enterprise value of $80M for the QuickFISH and Acuitas products, with a 15% discount rate and 2% terminal growth rate, excluding $1M debt.”
According to TipRanks.com, Selvaraju is ranked 0 out of 5 stars with an average return of -9.0% and a 33.8% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as Biospecifics Technologies Corp, EyePoint Pharmaceuticals Inc, and Bausch Health Companies Inc.
OpGen Inc has an analyst consensus of Moderate Buy, with a price target consensus of $6.
See today’s analyst top recommended stocks >>
Based on OpGen Inc’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $3.73 million. In comparison, last year the company had a GAAP net loss of $2.94 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
OpGen, Inc. operates as a precision medicine company using molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for global healthcare settings, helping to guide clinicians with more rapid and actionable information about life threatening infections, improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. The company was founded on January 22, 2001 and is headquartered in Gaithersburg, MD.
